4 Sep 2019 07:00
4 September 2019
AIM: AMYTEuronext Growth: AYP
Amryt Pharma plc
("Amryt" or the "Company")
Suspension of Trading on the Euronext Growth Market
Trading on AIM Unaffected
Amryt, a revenue-generating orphan drug company focused on acquiring, developing and commercialising products that help improve the lives of patients where there is a high unmet medical need has been informed that, with effect from the start of trading today, 4 September 2019, and lasting until 8.00pm on 20 September 2019 (being the "CVR Record Time"), certain Central Counterparties ("CCPs") will not be supporting the clearing of trades in Amryt's Ordinary Shares (ISIN: GB00BKB1MS30). Accordingly, in accordance with the requirements of Euronext Dublin, trading in the Ordinary Shares of Amryt will therefore be suspended on the Euronext Growth Market only with effect from 8.00am today until such time as the CVR Record Time has passed.
Trading in the Ordinary Shares on the AIM market of the London Stock Exchange ("AIM") will continue during this period and the Company does not expect that trading on AIM will be affected as a result.
Defined terms used but not defined in this announcement have the same meanings as those within the Admission Document published by the Company on 27 August 2019.
Enquiries:
Amryt Pharma plc | +353 (1) 518 0200 |
Dr. Joe Wiley, CEO Rory Nealon, CFO/COO | |
Davy | +353 (1) 679 6363 |
Euronext Growth Advisor and Joint Broker | |
John Frain, Daragh O'Reilly | |
Shore Capital | +44 (0) 20 7408 4090 |
Nominated Adviser and Joint Broker | |
Edward Mansfield, Mark Percy, Daniel Bush, John More
| |
Stifel | +44 (0) 20 7710 7600 |
Joint Broker | |
Jonathan Senior, Ben Maddison | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Amber Fennell, Matthew Neal, David Daley |
AMYT.L (AMYT)